LANGHORNE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the LD Micro Main Event XIX Conference being held at the Hotel Del Coronado in San Diego, California, on October 19-21, 2025. LD Micro Main Event XIX ...

Financial Performance - Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% compared to $1.44 million for the same period in 2024 [1][4] - Gross profit for the quarter was $1.26 million, with a gross profit margin of 43.6%, compared to a gross profit of $0.29 million and a margin of 20.3% for the same period in 2024 [6][8] - The net loss attributable to NEXGEL stockholders was $0.67 million, an improvement from a net loss of $0.89 million in Q2 2024 [9][8] Business Growth and Strategy - The year-over-year revenue growth was driven by increased consumer demand for branded products and new agreements in contract manufacturing [3] - The company expects significant growth opportunities in the second half of 2025 due to new consumer product launches and onboarding new contract manufacturing customers [3] - A partnership with STADA was expanded, including a $1 million advance in non-dilutive capital to support product launches and marketing efforts [10][3] Cost and Expenses - Cost of revenues for the second quarter of 2025 was $1.63 million, up from $1.15 million in Q2 2024, primarily due to sales growth in branded consumer products [5] - Selling, general and administrative expenses totaled $1.89 million for the second quarter of 2025, compared to $1.27 million for the same period in 2024, driven by increases in compensation, advertising, and professional fees [7] Future Outlook - The company is reiterating its revenue guidance for 2025 of $13 million and aims to achieve positive EBITDA during the year [1][3] - As of June 30, 2025, the company had a cash balance of approximately $0.73 million, with additional financing of $1.05 million secured to support growth initiatives [10]

Core Viewpoint - NEXGEL, Inc. is set to report its financial results for the second quarter of 2025 on August 12, 2025, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - The financial results for the second quarter of 2025 will be released after market close on August 12, 2025 [1]. - A conference call will be held at 4:30 P.M. ET on the same day to discuss the financial results [2]. Group 2: Company Overview - NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications [3]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [3]. - NEXGEL's product brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George, and it has strategic contract manufacturing relationships with major consumer healthcare companies [3].

Core Viewpoint - NEXGEL, Inc. has announced a definitive agreement for the issuance and sale of 413,044 shares of common stock at $2.30 per share, along with unregistered warrants for an additional 206,522 shares at an exercise price of $4.25, aimed at strengthening its balance sheet and providing working capital for anticipated growth in the second half of the year [1][2]. Group 1: Financial Details - The total number of shares being offered is 413,044 at a price of $2.30 each [1]. - Concurrently, NEXGEL will issue unregistered warrants to purchase up to 206,522 shares at an exercise price of $4.25, which are immediately exercisable for five years [1][2]. - The financing, combined with a recent $1 million non-dilutive advance from STADA, enhances the company's cash position [2]. Group 2: Regulatory Information - The shares are being offered under the company's shelf registration statement on Form S-3, which was declared effective by the SEC on June 7, 2023 [3]. - The unregistered warrants are offered under an exemption from registration requirements of the Securities Act [4]. Group 3: Company Overview - NEXGEL is a provider of healthcare, beauty, and OTC products, specializing in ultra-gentle, high-water-content hydrogels [6]. - The company has over two decades of experience in developing and manufacturing electron-beam, cross-linked hydrogels [6].

Company Overview - NEXGEL, Inc. is a leading provider of healthcare, beauty, and over-the-counter (OTC) products, specializing in ultra-gentle, high-water-content hydrogels [3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades [3] - NEXGEL's product brands include SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] - The company has established strategic contract manufacturing relationships with leading consumer healthcare companies [3] Event Participation - Adam Levy, the Chief Executive Officer of NEXGEL, will participate in the 6th Annual CEO Networking Event hosted by Semco Capital in Chicago on June 2, 2025 [1] - The event will feature a fireside chat with Scott Weis of Semco Capital [1] - The Annual CEO Networking Event aims to bring together leading microcap companies with unique business models and strong management teams [2]

Core Insights - NEXGEL, Inc. reported a significant revenue increase of 121% year-over-year for Q1 2025, totaling $2.81 million compared to $1.27 million in Q1 2024 [1][4][10] - The gross profit margin improved to 42.4% in Q1 2025, up from 12.6% in Q1 2024, indicating enhanced profitability [6][10] - The company aims to achieve $13 million in revenue for 2025 and expects to reach positive EBITDA during the year [3][10] Financial Performance - Revenue for Q1 2025 was $2.81 million, a 121% increase from $1.27 million in Q1 2024, driven by growth in both contract manufacturing and branded products [4][10] - Gross profit for the quarter was $1.19 million, compared to $0.16 million in Q1 2024, with a gross profit margin of 42.4% [6][10] - Cost of revenues increased to $1.62 million in Q1 2025 from $1.11 million in Q1 2024, aligning with revenue growth [5][10] Operating Expenses - Selling, general and administrative expenses rose to $1.96 million in Q1 2025 from $1.03 million in Q1 2024, attributed to higher compensation, marketing, and consulting fees [7][10] - EBITDA loss narrowed to ($0.54) million in Q1 2025 from ($0.84) million in Q1 2024, while adjusted EBITDA improved to ($0.47) million from ($0.73) million [8][10] Net Loss and Cash Position - The net loss for Q1 2025 was $0.71 million, an improvement from a net loss of $0.85 million in Q1 2024 [8][10] - As of March 31, 2025, the company had a cash balance of approximately $1.19 million [9][10] Future Outlook - The CEO highlighted multiple growth opportunities in contract manufacturing with existing customers and new product launches in consumer branded products [3][10] - The company remains confident in achieving its revenue guidance for 2025 and expects to improve its EBITDA performance [3][10]

Company Overview - NEXGEL, Inc. is a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications [3] - The company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades [3] - NEXGEL's product brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George [3] - The company has strategic contract manufacturing relationships with leading consumer healthcare companies [3] Financial Results Announcement - NEXGEL will report its financial results for the first quarter of 2025 after the market close on May 13, 2025 [1] - A conference call will be hosted by the company at 4:30 P.M. ET on the same day to discuss the financial results [1][2] - For those unable to join the live call, a replay will be available until May 27, 2025, with specific dial-in numbers provided [2]